Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2017). Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, randomized clinical trial. Diabetes Care , 41 (2), 258–266. https://doi.org/10.2337/dc17-0417 Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. Diabetes & Endocrinology , 7 (10), 776–785. https://doi.org/10.1016/s2213-8587(19)30249-9 Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism , 19 (9), 1242–1251. https://doi.org/10.1111/dom.12932 Urva, S., O’Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023b). The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism , 25 (9), 2784–2788. https://doi.org/10.1111/dom.15167

Information for Semaglutide

Semaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.

Order Semaglutide 5mg

Order Semaglutide 10mg

Certificates of Analysis

Semaglutide<br>12.07mg<br>Task #42392<br>Batch #04302024<br>05/08/2024

Semaglutide
12.07mg
Task #42392
Batch #04302024
05/08/2024

Semaglutide<br>10.27mg<br>Task #42384<br> Batch #04082024<br>04/12/2024

Semaglutide
10.27mg
Task #42384
Batch #04082024
04/12/2024

Semaglutide<br>10.49mg<br>Task #42386<br>Batch #04102024<br>04/16/2024

Semaglutide
10.49mg
Task #42386
Batch #04102024
04/16/2024

Semaglutide<br>5.66mg<br>Task #42243<br>Batch #05172024<br>05/17/2024

Semaglutide
5.66mg
Task #42243
Batch #05172024
05/17/2024

Semaglutide Peptide Structure

Sequence: HXEGTFTSDVSSYLEGQAAK-OH.steric diacid-EFIAWLVRGRG
Molecular Formula: C187H291N45O59
Molecular Weight: 4113.64 g/mol
PubChem CID: 56843331
CAS Number: 910463-68-2
Synonyms: Semaglutide, Oxempic, Rybelsus, NN9535

Order Semaglutide 5mg

Order Semaglutide 10mg

What Is Semaglutide?

Regulates blood glucose levels¹
Reduces body weight¹
Shows promise in cardioprotective treatment²

May suppress hunger and food cravings³
Delays gastric emptying⁴

Research Studies

Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2017). Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, randomized clinical trial. Diabetes Care, 41(2), 258–266. https://doi.org/10.2337/dc17-0417
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. Diabetes & Endocrinology, 7(10), 776–785. https://doi.org/10.1016/s2213-8587(19)30249-9
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 19(9), 1242–1251. https://doi.org/10.1111/dom.12932
Urva, S., O’Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023b). The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 25(9), 2784–2788. https://doi.org/10.1111/dom.15167

Product Usage

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Order Semaglutide 5mg

Order Semaglutide 10mg